Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome

Basit Öğe Kaydı
dc.contributor.authorAlan, Murat
dc.contributor.authorGurlek, Beril
dc.contributor.authorYilmaz, Alpay
dc.contributor.authorAksit, Murat
dc.contributor.authorAslanipour, Behnaz
dc.contributor.authorGulhan, Ibrahim
dc.contributor.authorMehmet, Calan
dc.contributor.authorTaner, Cuneyt Eftal
dc.date.accessioned2019-10-27T09:45:32Z
dc.date.available2019-10-27T09:45:32Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractAsprosin associated with insulin resistance is a newly discovered peptide hormone. The peptide promotes hepatic glucose production. Polycystic ovary syndrome (PCOS) is a metabolic disorder. Insulin resistance plays a vital role in the pathogenesis of the disease. The aim of this study was to discover the association between insulin resistance and asprosin in women with PCOS. We recruited 78 subjects with PCOS and 78 age-matched and body mass index (BMI)-matched controls into this cross-sectional study. Circulating asprosin levels were validated using ELISA method. We also determined metabolic and hormonal parameters of the involved subjects. We found that circulating asprosin levels were elevated in women with PCOS with respect to controls. Asprosin levels showed a positive correlation with insulin resistance, BMI, and free androgen index (FAI). Moreover, subjects with the highest tertile of asprosin levels represented increased odds of having PCOS as compared to those subjects with the lowest tertile asprosin levels. Increased asprosin levels resulted to high possibility of having PCOS risk associated with insulin resistance.en_US
dc.identifier.doi10.1080/09513590.2018.1512967
dc.identifier.endpage223en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issn0951-3590en_US
dc.identifier.issn1473-0766en_US
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage220en_US
dc.identifier.urihttps://doi.org/10.1080/09513590.2018.1512967
dc.identifier.urihttps://hdl.handle.net/11454/29157
dc.identifier.volume35en_US
dc.identifier.wosWOS:000462468300008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPolycystic ovary syndromeen_US
dc.subjectasprosinen_US
dc.subjectinsulin resistanceen_US
dc.subjectbody mass indexen_US
dc.titleAsprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu